Trial Profile
A Phase 2, Randomized, Placebo-Controlled, Double-blind Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ivacaftor/tezacaftor (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- Sponsors Vertex Pharmaceuticals
- 23 Aug 2018 Status changed from active, no longer recruiting to completed.
- 07 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 06 Oct 2016 Planned End Date changed from 1 May 2018 to 1 Oct 2018.